Circulating Sulfatide, A Novel Biomarker for ST-Segment Elevation Myocardial Infarction

Area of Science:

• Cardiology
• Biochemistry
• Clinical Medicine

Background:

• ST-segment elevation myocardial infarction (STEMI) is an acute inflammatory and thrombotic cardiovascular disease.
• Serum sulfatides are implicated in inflammation, thrombogenesis, and atherosclerosis.
• Elevated serum sulfatides levels were observed in STEMI patients.

Purpose of the Study:

• To investigate the relationship between serum sulfatides levels and clinical outcomes in STEMI patients.
• To determine if serum sulfatides can predict adverse cardiovascular events in STEMI.

Main Methods:

• Serum sulfatides levels were measured in 370 STEMI inpatients within 24 hours of onset.
• Patients were categorized into low (≤15.2 µmol/L) and high (>15.2 µmol/L) sulfatide groups.
• Clinical outcomes, including in-hospital death and major adverse cardiovascular events (MACE), were analyzed using logistic and Cox regression.

Main Results:

• High serum sulfatides levels correlated with an increased rate of in-hospital death (OR 0.971, p=0.019).
• Patients with high sulfatides showed higher cumulative incidences of target vessel revascularization (TVR) (23% vs. 8%) and overall MACE (28% vs. 10%).
• Multivariate analysis confirmed high serum sulfatides as a predictor for TVR and MACE.

Conclusions:

• Elevated serum sulfatides levels are positively associated with in-hospital mortality in STEMI patients.
• High serum sulfatides are linked to increased risks of TVR and MACE in STEMI.
• Serum sulfatides may serve as a prognostic biomarker for adverse outcomes in STEMI.